Immune Netw.  2004 Sep;4(3):161-165. 10.4110/in.2004.4.3.161.

Effect of beta2-GP1 on the Binding of Anti-cardiolipin Antibodies to Cardiolipin

• Kang EY
• Jang YJ

• KMID: 2167977
• DOI: http://doi.org/10.4110/in.2004.4.3.161

Abstract

BACKGROUND
Anti-cardiolipin antibody (Anti-CL Ab) is one of the various anti-phospholipid antibodies (Anti-PL Abs) and found in the plasma of patients with systemic lupus erythematosus (SLE), atherosclerosis, and other infectious diseases. While anti-PL Abs found in the sera of patients with infectious diseases bind directly to CL, binding of anti-PL Abs to CL circulating in the sera of patients with autoimmune diseases is mediated by beta2-glycoprotein 1 (beta2-GP1). The purpose of this study is to investigate the effect of beta2-GP1 on the antigen binding assay of anti-CL Abs present in the sera of patients with atherosclerosis, which has been known as one of autoimmune diseases. METHODS: ELISA was performed with sera containing anti-CL Abs from three patients with atherosclerosis in the presence or absence of beta2-GP1 or FBS. RESULTS: Reactivity of anti-CL Abs to CL was increased in the presence of beta2-GP1 or FBS in a dose dependent manner. CONCLUSION: beta2-GP1 or FBS could be used as co-factor in CL ELISA with anti-CL Abs present in the sera of patients with atherosclerosis. It is suggested that anti-CL Abs found in atherosclerosis patients are similar in terms of antigen binding property to those circulating in the patients with autoimmune diseases, not to infectious diseases.

Keyword

Anti-CL; anti-PL; atherosclerosis; co-factor; beta2-GP1; FBS

MeSH Terms

Antibodies*
Atherosclerosis
Autoimmune Diseases
Cardiolipins*
Communicable Diseases
Enzyme-Linked Immunosorbent Assay
Humans
Lupus Erythematosus, Systemic
Plasma
Antibodies
Cardiolipins